TREATMENT
Liquid biopsy guides anti-EGFR rechallenge in real-world metastatic CRCIn 104 patients with RAS/BRAF wild-type metastatic colorectal cancer, circulating tumor DNA testing identified candidates for anti-EGFR rechallenge, leading to a 29% response rate and improved overall survival (21.9 vs 11.1 months) compared to standard-of-care treatments. (European Journal of Cancer)